Investigational Site Number :5780001
Oslo 0450
2 studies enrolling now · 12 studies all time
What they study most
Chronic Inflammatory Demyelinating Polyneuropathy, Hypercholesterolaemia, Neoplasm Malignant, Non-relapsing Secondary Progressive Multiple Sclerosis, Plasma Cell Myeloma, Plasma Cell Myeloma Recurrent, Plasma Cell Myeloma Refractory, Progressive Relapsing Multiple Sclerosis, Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Type 2 Diabetes Mellitus
Studies at this site
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
- Isatuximab in Combination With Novel Agents in RRMM - Master Protocol — Recruiting now
- First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL — Completed
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — Running, not enrolling
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma — Running, not enrolling
- SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM — Running, not enrolling
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) — Completed
- Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) — Completed
- Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients — Completed
- An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia — Completed
- Effect of Efpeglenatide on Cardiovascular Outcomes — Stopped early
- An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia — Completed